definiens: shall mean the method and experimental protocol providing a means to measure tihPdy - dependent cellular cytotoxic activiti}>f the SINGLE - CHAIN A TIBODY supplied by MICROMET to BIOV A TION in the context of a BiTE 1/19 CONFIDENTIAL TRE, ATMENT REQUESTED c~\ ( b ) shall mean a single - chain bispecific antibody format proprietary to MICROMET consisting of the SINGLE - CHAIN ANTIBODY connected via a peptide linker to a second single - chain antibody binding to a target cell antigen ( c ) shall mean all patent applications and granted patents relevant to which are or become owned by BIOYATION, or to which BIOYATION otherwise has, now or in the future, the right to grant licences, and which generically or specifically claim TECHNICAL INFORMATION, technology, products or a composition comprising products, a process for manufacturing or formulating a product, an intermediate used in such process or a use of product or a technology, as well as all other intellectual property rights arising therefrom, including, but not limited to, all continuations in part, divisional applications, and future patents issuing thereon, corresponding foreign patent applications and patents, all reissues, re - examinations, extensions, including supplementary protection certificates and including, but not limited to, the PATENT RIGHTS ( d ) shall mean each bispecific antibody developed by coupling the DEIMMUNISED ANTIBODY ( or portion thereof ) with another antibody ( or portion thereof ) ( e ) shall mean all information disclosed by MICRO MET to BIOY A TION with reference to the SINGLE­CHAIN ANTIBODY, whether such information is in tangible or intangible form, including non - technical or technical information, trade secrets, know - how, inventions, processes and samples . CONFIDENTIAL INFORMATION shall include any oral disclosure provided such oral disclosure is reduced to writing and given to BIOV ATION in written form within 30 days after oral disclosure